Table 1.
Urban area |
Rural area |
|||
---|---|---|---|---|
Pre-COVID-19
|
COVID-19 period
|
Pre-COVID-19
|
COVID-19 period
|
|
Type of vaccine
|
% (95% CI)
|
% (95% CI)
|
% (95% CI)
|
% (95% CI)
|
DPT1/penta1 vaccine |
94.5 (88.7–97.4) |
91.2 (85.6–94.8) |
94.9 (90.6–97.3) |
88.3 (80.2–93.3) |
DPT2/penta2 vaccine |
86.5 (80.6–90.8) |
90.5 (85.2–94.0) |
90.6 (84.1–94.7) |
88.6 (81.9–93.0) |
DTP3/penta3 vaccine |
73.3 (66.0–79.6) |
88.3 (83.1–92.1) |
84.9 (76.8–90.6) |
87.1 (80.3–91.8) |
Measles vaccine |
83.5 (73.9–90.0) |
83.4 (80.0–86.3) |
81.3 (71.0–88.5) |
83.6 (77.1–88.5) |
Dropout between DPT1 and DPT3 |
16.0 (11.3–22.0) |
3.6 (1.7–7.6) |
6.3 (3.1–12.5) |
3.5 (1.9–6.4) |
DPT1 vaccine taken on time (6–11 weeks) |
55.0 (45.2–64.4) |
58.7 (50.6–66.3) |
67.4 (58.0–75.6) |
52.5 (41.3–63.4) |
DPT2 vaccine taken on time (10–19 weeks) |
63.8 (55.1–71.6) |
68.6 (62.1–74.5) |
67.4 (59.2–74.7) |
63.8 (55.3–71.5) |
DPT3 vaccine taken on time (14–24 weeks) |
49.1 (41.6–56.8) |
65.2 (58.6–71.2) |
65.5 (55.2–74.5) |
58.9 (50.4–67.0) |
Measles vaccine taken on time (6–12 months) | 44.9 (36.8–53.3) | 56.4 (48.1–64.4) | 49.2 (38.1–60.5) | 51.4 (42.1–60.6) |
DPT – diphtheria, pertussis, and tetanus